Author

Xiaoshi Zhang

Observed names: Xiao-Shi Zhang, Xiao-shi Zhang

Institutions: Sun Yat-sen University, Jilin Province Tumor Hospital, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

Observed institutions: Sun Yat-sen University, Capital Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Chao-Yang Hospital, Capital Medical University, West China Hospital of Sichuan University, Jilin Province Tumor Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

ORCID: 0000-0002-2306-8011

Observed ORCID: 0000-0002-2306-8011

OpenAlex ID: A5101900689

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

2025 · Run-Cong Nie, Shu-Qiang Yuan, et al. · Signal Transduction and Targeted Therapy · 21

Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study

2024 · Xiaoshi Zhang, Xiaodong Zhu, et al. · Scientific Reports · 13

MiR-374b-5p inhibits KDM5B-induced epithelial-mesenchymal transition in pancreatic cancer.

2021 · Xin Zhao, Xiaoshi Zhang, et al. · PubMed · 13

Efficacy of PD-1 Inhibitors for Colorectal Cancer and Polyps in Lynch Syndrome Patients

2023 · Jiehai Yu, Binyi Xiao, et al. · SSRN Electronic Journal · 2

The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation

2021 · Tao Jiang, Xiao-shi Zhang, et al. · Medicine · 2

A multicenter, randomized, controlled, open-label, phase 2 study of the PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in mucosal and acral melanoma.

2025 · Bin Lian, Yu Chen, et al. · Journal of Clinical Oncology · 1

Perioperative PD-1 antibody tislelizumab plus chemotherapy for locally advanced gastro-oesophageal junction cancer: A prospective, nonrandomized, open-label, phase II trial.

2024 · Run-Cong Nie, Ya Ding, et al. · Journal of Clinical Oncology · 1

Preliminary results from phase 2 study of prolonged neoadjuvant immunotherapy plus chemotherapy in Borrmann type 4 and large type 3 gastric cancer (Neo-ICEBOAT Study).

2025 · Chao Ding, Dandan Li, et al. · Journal of Clinical Oncology

Efficacy and safety of transcatheter arterial infusion of immune checkpoint inhibitors in locoregional unresectable or in-transit acral melanoma: A multi-center real-world study.

2025 · Ziluan Chen, Lujun Shen, et al. · Journal of Clinical Oncology

Pyroptosis-related pattern depicting tumor microenvironment and association with prognosis and efficacy in patients with hepatocellular carcinoma receiving combined molecular targeted therapy and immune checkpoint inhibitors: A multi-omics study.

2024 · Bowen Xu, Yanjiang Yin, et al. · Journal of Clinical Oncology

Works count: 10

Citation count: 53

H-index: 3

I10-index: 3